Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

me period in 2008. GAAP net loss per share for the six months ended June 30, 2009 was $0.56 per share, basic and diluted, compared to a GAAP net income per share of $0.56, basic, and $0.51, diluted, for the same period in 2008.

Non-GAAP adjusted net income in the three and six months ended June 30, 2009 was $34.5 million and $46.0 million, respectively, compared to $28.9 million and $51.0 million, respectively, for the same periods in 2008.

The primary drivers of the GAAP net loss in the six months ended June 30, 2009 was the impairment of goodwill for $65.1 million, offset by the gain on our repurchase of our senior convertible notes of $9.1 million. Contributing to this loss were launch costs for Cinryze, increased expenses relating to the development of our product pipeline, and the increase in amortization expense. GAAP net income decreased for the second quarter of 2009 as compared to 2008 due to a decrease in Vancocin sales, increased SG&A costs related to the launch of Cinryze, increased amortization and lower interest income, partially offset by Cinryze sales.

Effective January 1, 2009, the Company adopted Financial Accounting Standards Board's Staff Position No. APB 14-1, "Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)" ("FSP APB 14-1"), which changed the method of accounting for the Company's convertible notes. The Company revised its previously reported financial statements to apply this change in accounting to prior periods. Under this new accounting method, the Company's EPS and net (loss) income calculated in accordance with GAAP have been reduced as a result of recognizing incremental non-cash interest expense. In connection with adopting FSP APB 14-1, the Company recorded $1.7 million and $2.0 million of additional non-cash interest expense in the three months ended June 30, 2009 and 2008, respectively, and $3
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
(Date:12/20/2014)... 20, 2014 Today, Balfleet.com, one of ... Christmas Sale, offering 50%-70% off on its Mother ... , The mother of the bride dresses from Balfleet.com ... is 24/7 accessible and takes pride in providing high ... “We are offering great discounts on our mother of ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up with the ... 28th from 2pm-6pm at the Expo Center on the northeast ... , Inquiries regarding time slots and signing up, email todd.subzeroicecream(at)gmail(dot)com. ... process, Sub Zero Ice Cream & Yogurt will be offering ... About Sub Zero Ice Cream & Yogurt , Sub ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... 2014 The Medspa at Hendrick in ... from respected cosmetic brand Juvéderm. Voluma XC treats volume ... The Medspa at Hendrick is pleased to be able ... technology to its clients. , Voluma is the first ... to treat the mid-face and cheek area. This non-invasive ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... either way because of salty sauces , , MONDAY, Oct. 20 ... that are staples of the Western diet account for about ... new report suggests. , Meanwhile, a diet rich in fruits ... risk of heart attack, according to the study, published in ...
... heart attacks , , MONDAY, Oct. 20 (HealthDay News) -- A ... reduce the risks of surgery. , The death rate for ... higher in the 30 days after an operation than for ... according to a report in the October issue of the ...
... risk of chronic diseases and,can help reduce health care ... Oct. 20 Small steps can lead to big,health ... campaign,launched today. As families stretch to make ends meet ... American Medical Association,s campaign,can help people live a healthy ...
... 20 Lincare Holdings,Inc. (Nasdaq: LNCR ), a ... to patients in the home, today announced,financial results for ... For the quarter ended September 30, 2008, revenues ... the third quarter of 2007. The,Company estimates that the ...
... 20 Insulet Corporation,(Nasdaq: PODD ), the leader ... today announced the appointment of Sally W.,Crawford to its ... the former chief operating officer of Healthsource Inc., a ... Partners, a venture,capital firm in life sciences, on Insulet,s ...
... play a major role, study suggests , , MONDAY, Oct. ... likely to die in U.S. emergency rooms after a ... uninsured ER patients are more likely to die compared ... October issue of the Archives of Surgery . ...
Cached Medicine News:Health News:Western Diet Boosts Global Heart Attack Risk 30% 2Health News:Questions Continue About Using Beta Blockers Before Surgery 2Health News:Questions Continue About Using Beta Blockers Before Surgery 3Health News:AMA Aims to Help Americans Get Healthier One Step at a Time 2Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 2Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 3Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 4Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 5Health News:Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2008 Financial Results 6Health News:Sally W. Crawford Joins Insulet's Board of Directors 2Health News:Sally W. Crawford Joins Insulet's Board of Directors 3Health News:Sally W. Crawford Joins Insulet's Board of Directors 4Health News:Minorities More Likely to Die in ER 2Health News:Minorities More Likely to Die in ER 3
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)... 2014 With advancements in neurological and ... is seeing new growth, according to Kalorama Information. ... for the majority of market volume, newer 3T ... which are creating opportunities for more sophisticated applications. The ... at a rate of 4%, with world market ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
PremierEdge Stab Knives - 30....
PremierEdge™ Stab Knives - 15°....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: